Your browser is outdated!

To ensure you have the best experience and security possible, update your browser. Update now

×

Shravan Parsi

Founder and CEO, American Ventures

Shravan Parsi
Austin United States (Texas)
Professional Status
Employed
Available
About Me
Shravan Parsi is the founder and CEO of American Ventures, an Austin-based firm that invests in and develops multifamily, mixed-use, commercial, and hospitality real estate along the Austin-San Antonio corridor.

He has invested in Texas real estate since 2003. Alongside private equity groups, family offices, and accredited investors, he acquired 22 apartment complexes totaling roughly 4,400 units, then took the value-add portfolio full cycle across two market peaks, with every investor paid back.

Parsi trained as a pharmaceutical scientist, and he underwrites the way he once ran experiments: a written protocol, the same disqualifying criteria on every deal, and stress tests built to kill a deal before capital is committed. He laid out the method in The Science of the Deal, published by Forbes Books in 2019.

Today the firm's work is mostly development. About $600 million in planned projects includes a Marriott Tribute hotel and condominium site on Austin's South Congress Avenue, a mixed-use district in San Marcos, and more than 60 acres in Elgin. American Ventures has 252 high-net-worth investor relationships, about one third of them repeat investors.
Resume created on DoYouBuzz
  • Multifamily and commercial acquisitions
  • Written underwriting protocols and stress testing
  • Texas submarket, supply, and absorption analysis
  • Replacement cost versus acquisition pricing
  • Disposition timing and full-cycle exits
  • Ground-up multifamily development
  • Mixed-use and master-planned districts
  • Hospitality development and hotel brand selection
  • Land assembly and entitlements
  • Equity raising from high-net-worth investors, family offices, and private equity
  • Institutional co-investment and joint ventures
  • HUD and long-term fixed-rate financing
  • Deal structuring and operating agreements
  • Investor reporting
  • Value-add repositioning
  • Workforce housing operations
  • Hold-period business plan revisions
  • Documentation and repeatable process, carried over from pharmaceutical R&D